Lacosamide Krka (Lacosamide)

Lacosamide is an antiepileptic drug that modulates neuronal excitability in seizure disorders.

• Partial‑onset seizures: reduces seizure frequency when used as adjunct therapy.
• Epilepsy (refractory): provides additional seizure control in patients not fully managed by other agents.
• Adjunctive therapy for focal epilepsy: enhances overall seizure management when combined with other antiepileptics.

• Lacosamide enhances the slow inactivation of voltage‑gated sodium channels, stabilizing neuronal membranes and decreasing hyper‑excitability. By selectively targeting the persistent sodium current, it limits repetitive neuronal firing that underlies seizure activity, without markedly affecting normal neuronal conduction.

Lacosamide may cause a range of adverse reactions, from mild to serious.

Common Side Effects

• Dizziness: sensation of light‑headedness or unsteadiness.
• Nausea: mild to moderate upset stomach.
• Headache: persistent or intermittent pain.
• Fatigue: increased tiredness or lack of energy.
• Blurred vision: temporary visual disturbances.
• Diplopia: double vision in some patients.

Serious or Rare Side Effects

• Suicidal thoughts: emergence of depressive symptoms or suicidal ideation.
• Severe rash: including Stevens‑Johnson syndrome.
• Cardiac arrhythmia: especially PR‑interval prolongation.
• Respiratory depression: marked slowing of breathing.
• Anaphylaxis: acute allergic reaction with hives, swelling, or difficulty breathing.
• Hepatotoxicity: signs of liver injury such as jaundice.

Before initiating Lacosamide, clinicians should evaluate several safety considerations.

• Renal impairment: adjust dose in patients with reduced kidney function.
• Hepatic impairment: monitor liver enzymes and consider dose modification.
• Cardiac conduction: obtain baseline ECG; avoid in patients with significant PR‑interval prolongation.
• Pregnancy: use only if potential benefit justifies potential risk; data are limited.
• Concomitant CNS depressants: monitor for enhanced sedation or respiratory effects.
• Store at ambient temperature: keep below 25 °C, in the original packaging, protected from moisture and direct sunlight.

Lacosamide can interact with other medicines, requiring careful management.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase lacosamide plasma levels.
• Strong CYP3A4 inducers (e.g., carbamazepine): may reduce efficacy.
• Other sodium‑channel blockers (e.g., phenytoin): risk of additive cardiac effects.

Moderate Interactions (Monitor Closely)

• Opioids: potential for enhanced CNS depression.
• Alcohol: may increase dizziness and sedation.
• Anticoagulants (e.g., warfarin): monitor INR for possible changes.
• Antidepressants (e.g., SSRIs): watch for mood alterations.
• Diuretics: may affect electrolyte balance influencing cardiac conduction.